Ketamine for Anxiety Disorders: Mechanisms and Clinical Evidence

Can Ketamine Treat Anxiety Disorders?

Ketamine is being studied and used off-label as a rapid-acting treatment for several anxiety disorders, including generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. Unlike SSRIs and SNRIs, which typically take four to six weeks to produce a therapeutic effect, ketamine can reduce anxiety symptoms within hours to days by acting on the brain's glutamate system rather than serotonin or norepinephrine pathways. According to the World Health Organization, anxiety disorders affected an estimated 301 million people worldwide in 2023, making them the most common category of mental health condition. This article reviews the neurobiological rationale for ketamine's anxiolytic effects, summarizes the clinical evidence across specific anxiety disorders, and outlines what patients and clinicians should know before considering treatment. For background on the drug itself, see our complete guide to ketamine.

Why Standard Anxiety Treatments Fall Short for Some Patients

Generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobias, and agoraphobia are each defined, according to the National Institute of Mental Health, by excessive fear, worry, or avoidance that interferes with daily functioning. First-line treatments include SSRIs, SNRIs, buspirone, and cognitive behavioral therapy (CBT), and these approaches help many patients. But SSRIs and SNRIs typically require four to six weeks to reach full effect, and an estimated 30 to 40 percent of patients with anxiety disorders do not achieve adequate symptom relief with conventional pharmacotherapy. That treatment gap is what has driven clinical interest in ketamine as a faster-acting option. See our comparison of ketamine versus SSRIs for a closer look at how the two approaches differ in onset, mechanism, and side effect profile.

The Neurobiology of Anxiety: Glutamate and NMDA Receptors

Anxiety disorders are associated with altered glutamate signaling in brain regions that process threat, including the amygdala, prefrontal cortex, and hippocampus. Elevated glutamate activity in the amygdala has been linked to heightened fear responses, while reduced glutamatergic tone in the prefrontal cortex may impair the brain's ability to regulate anxiety. NMDA receptors, a subtype of glutamate receptor that ketamine blocks, are heavily expressed in these anxiety-related circuits. Preclinical studies have shown that blocking NMDA receptor activity in the amygdala can reduce conditioned fear responses in animal models, giving researchers a neurobiological rationale for testing ketamine as an anxiolytic. For a full explanation of this mechanism, see how ketamine works in the brain.

GABA, Excitatory-Inhibitory Balance, and Synaptic Plasticity

Anxiety has long been linked to an imbalance between excitatory glutamate signaling and inhibitory gamma-aminobutyric acid (GABA) signaling. Benzodiazepines, a traditional class of anxiolytics, work by enhancing GABA activity. Ketamine takes a different route: by briefly blocking NMDA receptors on GABAergic interneurons, it produces a temporary surge in glutamate release that activates AMPA receptors. That cascade triggers release of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of neurons, and activates the mTOR signaling pathway, which promotes synaptogenesis, the formation of new synaptic connections. This neuroplastic response is thought to help restore healthier circuit function in the brain regions implicated in anxiety. Our explainer on BDNF and ketamine covers this process in more detail.

Clinical Evidence Across Anxiety Disorders

A randomized controlled trial published in the Journal of Psychopharmacology in 2017 found that a single intravenous ketamine infusion (0.5 mg/kg over 40 minutes) produced significant reductions in anxiety symptoms among patients with generalized anxiety disorder and social anxiety disorder, with effects lasting up to seven days. A 2020 meta-analysis found consistent anxiolytic effects of ketamine across multiple studies, with effect sizes comparable to those seen in depression trials, though the total number of anxiety-specific trials remains small. Preliminary research on social anxiety disorder has reported reduced anticipatory anxiety and improved ease in social situations following treatment, which researchers attribute to ketamine's effects on prefrontal-amygdala circuitry involved in social threat processing. Evidence for panic disorder is more limited but growing: case reports and small open-label studies have documented reductions in panic attack frequency and severity after ketamine infusions, and the drug's rapid onset makes it an appealing option when acute symptom relief is a priority.

Anxiety as a Comorbid Condition in Depression Research

Much of the existing evidence for ketamine's anxiolytic effects comes from depression trials in which anxiety was tracked as a secondary outcome. A substantial share of patients with treatment-resistant depression also meet criteria for a comorbid anxiety disorder. In these populations, ketamine has consistently produced concurrent reductions in both depressive and anxiety symptoms, which suggests its anxiolytic effect is not simply a byproduct of improved mood. For more on how ketamine performs in depression specifically, see our review of ketamine for treatment-resistant depression.

Mechanisms Behind the Anxiolytic Effect

Functional neuroimaging studies show that ketamine increases connectivity between the prefrontal cortex and limbic structures such as the amygdala. Stronger prefrontal-amygdala connectivity is associated with better emotion regulation, a core deficit in anxiety disorders, so this strengthened top-down control may help the brain modulate fear responses more effectively. Ketamine may also support fear extinction, the process by which learned fear responses weaken through repeated exposure without negative consequences. NMDA receptor activity is known to be important for fear extinction learning, and while ketamine blocks these receptors acutely, the neuroplastic changes it sets off in the following hours and days may enhance the brain's capacity for extinction. Some researchers have proposed administering ketamine before exposure-based psychotherapy sessions to take advantage of this window. A third mechanism involves inflammation: elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) have been observed in patients with anxiety disorders, and ketamine has shown anti-inflammatory properties in preclinical and clinical research. This anti-inflammatory action may contribute to its anxiolytic effect, particularly in patients with elevated inflammatory markers at baseline. Our article on ketamine and neuroinflammation covers this mechanism in depth.

Dosing, Dissociation, and Duration of Effects

No dosing protocol for anxiety disorders has been definitively established. Most clinical studies have used the standard depression protocol of 0.5 mg/kg intravenously over 40 minutes and observed anxiolytic effects alongside mood improvement. According to MedlinePlus, ketamine injection is FDA-approved only as a general anesthetic, so its use for anxiety or depression is off-label. Some clinicians report that lower doses may be sufficient for anxiety-predominant presentations, though this remains an area of active investigation rather than settled practice. Dissociation, the altered sense of self or surroundings that ketamine commonly produces, deserves particular attention in anxiety treatment. For some patients, the dissociative experience itself can provoke anxiety, especially during early sessions. Careful preparation, a calm treatment environment, and experienced clinical support can help minimize treatment-related distress, and many clinicians report that anxiety during infusions tends to decrease as patients become familiar with the experience over subsequent sessions. Our guide to understanding dissociation covers what to expect during treatment. Anxiolytic effects from a single infusion have been reported to last from several days to roughly two weeks, though duration varies by individual and anxiety subtype. As with depression treatment, clinicians typically use a series of infusions followed by maintenance dosing to sustain benefit.

Current Limitations and Future Directions

The evidence for ketamine in anxiety disorders is promising but less developed than the evidence for depression. Several gaps remain:

• Most studies to date have been small and short in duration
• No FDA-approved indication exists for ketamine or esketamine specifically for anxiety disorders
• Optimal dosing, route of administration, and treatment frequency for anxiety are not yet defined
• Long-term safety data specific to anxiety populations are limited
• Ketamine can worsen anxiety symptoms in some individuals, which makes careful patient selection important

Ongoing and planned clinical trials are expected to strengthen this evidence base. Researchers are studying ketamine's efficacy across specific anxiety diagnoses, testing combination approaches with psychotherapy, and looking for biomarkers that might predict which patients are most likely to respond.

Combining Ketamine With Psychotherapy

Pairing ketamine with psychotherapy is one of the more active areas of anxiety treatment research. The period of heightened neuroplasticity that follows ketamine administration, often described as lasting 24 to 72 hours, may offer a window during which therapeutic learning is easier to consolidate. Clinicians who combine ketamine with evidence-based approaches such as CBT or acceptance and commitment therapy (ACT), an approach sometimes delivered as ketamine-assisted psychotherapy, report improved outcomes, though controlled studies confirming this combined benefit are still needed.